Safety and efficacy of subcutaneous injection with HMI-115 versus placebo in endometriosis-associated pain in premenopausal women: a multicentre, double-blind, randomised, proof-of-concept phase 2 trial

Condition tags

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (29)

• A systematic literature review on patient-reported outcome domains and measures in nonsurgical efficacy trials related to chronic pain associated with endometriosis: an urgent call to action via openalex
• Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis via openalex
• Dosage aspects of danazol therapy in endometriosis: Short-term and long-term effectiveness via openalex
• Elagolix Treatment for Endometriosis-Associated Pain: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study via openalex
• Endometriosis via openalex
• Medical management of endometriosis via openalex
• Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal Women via openalex
• Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2) via openalex
• Patient Preferences for Endometriosis Pain Treatments in the United States via openalex
• Progestins in the symptomatic management of endometriosis: a meta-analysis on their effectiveness and safety via openalex
• Prolactin and pain of endometriosis via openalex
• Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis via openalex
• The direct and indirect costs associated with endometriosis: a systematic literature review via openalex
• The effects of prolactin receptor blockade in a murine endometriosis interna model via openalex
• The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications via openalex
• Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist via openalex
• Use of a murine endometriosis interna model for the characterization of compounds that effectively treat human endometriosis via openalex
• W2034407873 via openalex
• W2200202512 via openalex
• W3004643744 via openalex
• W3013010875 via openalex
• W3194419458 via openalex
• W4214754424 via openalex
• W4234160457 via openalex
• W4293177412 via openalex
• W4312356190 via openalex
• W4403007827 via openalex
• W4407141431 via openalex
• W2116973468 via openalex

Cited by (2)

• Pathological roles of prolactin signaling in gynecologic and female-predominant diseases and prospects for targeted therapy 2026
• Novel targets for endometriosis-associated pain 2025

Source provenance

openalex

last seen: 2026-06-04T00:00:01.174412+00:00